DelveInsight Business Research LLP: Huntington's Disease Market to Witness Upsurge in Growth at a Tremendous CAGR of 18.4% During the Study Period (2019-2032), Predicts DelveInsight

The growth of the Huntington's disease market is expected to be mainly driven by less competitive scenarios, entry of innovative emerging therapies, rising prevalence, and geriatric population, increasing initiatives for R&D, and the advent of genetic testing

LAS VEGAS, Jan. 25, 2023 /PRNewswire/ -- DelveInsight's Huntington's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Huntington's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Huntington's Disease Market Report

As per DelveInsight analysis, the Huntington's disease market size in the 7MM was approximately USD 199 million in 2021.
According to the assessment done by DelveInsight, the estimated total Huntington's disease prevalent population in the 7MM was approximately 80K in 2021.
Globally, leading Huntington's disease companies such as Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Wave life sciences, Takeda, Medesis Pharm, Ionis Pharmaceuticals, PTC Therapeutics, Novartis, Neurimmune Therapeutics, SOLA Biosciences, Roche, AOP Orphan, Azevan Pharmaceuticals, Asklepios BioPharmaceutical, BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others are developing novel Huntington's Disease drugs that can be available in the Huntington's disease market in the coming years.
The promising Huntington's disease therapies in the pipeline include ACR-16 (pridopidine), INGREZZA (valbenazine/NBI-98854), ANX005, SOM3355 (bevantolol), VX15/2503 (pepinemab), SAGE-718, AMT-130 (rAAV5-miHTT), WVE-003 (mHTT SNP3), NP03 (nanolithium)/NanosiRNA, and others.
In October 2021, SOM Biotech announced that the US FDA had granted Orphan Drug Designation (ODD) for SOM3355 for the treatment of chorea movements in HD.
In October 2021, Annexon was granted orphan drug designation for the treatment of Huntington's disease by the US FDA.
In September 2021, Sage Therapeutics announced that the US FDA had granted Fast Track Designation to SAGE-718 for development as a potential treatment for HD.
In August 2016, the US FDA granted Fast-track Designation and Orphan drug designation to pepinemab for the treatment of Huntington's disease.

Discover which therapies are expected to grab the major Huntington's disease market share @ Huntington's Disease Market Report

Huntington's Disease Overview

Huntington's disease is a rare, inherited condition that results in the progressive breakdown (degeneration) of brain nerve cells. It is an autosomal dominant disorder caused by a single defective gene on chromosome 4. Involuntary jerking or writhing movements (chorea), muscle problems such as rigidity or muscle contracture (dystonia), slow or abnormal eye movements, impaired balance, difficulty speaking or swallowing, difficulty organizing, prioritizing or focusing on tasks, and fatigue and loss of energy are all common Huntington's disease symptoms. A general physical examination, medical history, and comprehensive neurological and psychiatric examinations are used for Huntington's disease diagnosis.

Huntington's Disease Epidemiology Segmentation

DelveInsight estimates that there were approximately 80Kprevalent cases of Huntington's disease in the 7MM in 2021.

In the 7MM, the most prevalent cases of Huntington's disease were found in the US, followed by Germany.

The Huntington's disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

Total prevalent cases
Total diagnosed prevalent cases
Total chorea-associated cases
Total age group-specific cases
Total clinical stage-specific cases
Total treated cases

Download the report to understand which factors are driving Huntington's disease epidemiology trends @ Huntington's Disease Epidemiological Insights

Huntington's Disease Treatment Market

Currently available Huntington's disease treatments include a variety of drug classes that can help patients manage their symptoms, such as movement, cognitive, and psychiatric issues. Medication can help with issues such as low mood (depression), anxiety, irritability (short temper), and jerky movements. Many of these drugs are being used off-label, with limited access to complete safety and efficacy data. A multidisciplinary approach that includes a neurologist, psychiatrist, genetic counseling, physical therapy, occupational therapy, speech therapy, and other specialized fields can help develop a plan and address a patient's unique needs. There are two types of Huntington's disease treatment: pharmacological and non-pharmacological. The first involves drug classes such as antidepressants, antipsychotics, mood stabilizers, and others.

The most common treatments for anxiety and depression are Selective serotonin reuptake inhibitors (SSRIs), which increase the amount of a chemical in the brain called serotonin. Citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), and sertraline (Zoloft) are a few examples of antidepressants. These medications may also help with the treatment of obsessive-compulsive disorder. Nausea, diarrhea, drowsiness, and low blood pressure are all possible side effects.

Antipsychotic drugs are used to treat outbursts, agitation, and hallucinations; your doctor may recommend quetiapine (Seroquel), haloperidol (Haldol), thorazine (chlorpromazine), risperidone (Risperdal), and olanzapine (Zyprexa). Because they suppress chorea, some of these drugs are frequently used off-label for Huntington's disease treatment.

To know more about Huntington's disease treatment guidelines, visit @ Huntington's Disease Management

Huntington's Disease Pipeline Therapies and Key Companies

ACR-16 (pridopidine): Prilenia Therapeutics
Ingrezza (valbenazine/NBI-98854): Neurocrine Biosciences
ANX005: Annexon Biosciences
SOM3355 (bevantolol): SOM Biotech
VX15/2503 (pepinemab): Vaccinex
SAGE-718: Sage Therapeutics
AMT-130 (rAAV5-miHTT): UniQure Biopharma
WVE-003 (mHTT SNP3): Wave life sciences/Takeda
NP03 (nanolithium)/NanosiRNA: Medesis Pharma

Learn more about the FDA-approved drugs for Huntington's disease @ Drug Treatment for Huntington's Disease

Huntington's Disease Market Dynamics

The dynamics of Huntington's disease is expected to change in the coming years. As Huntington's disease is a rare condition, companies developing Huntington's disease treatment options for it can benefit from several advantages, including premium pricing, Orphan Designation, which provides seven years of market exclusivity in the United States, clinical trial subsidies, reduced regulatory fees, and other perks.

Moreover, as adult-onset Huntington's disease is more common than juvenile Huntington's disease, more elderly patients will be diagnosed with HD knowledge as the geriatric population grows. Furthermore, less competitive scenarios, entry of innovative emerging therapies, increasing initiatives for R&D, and the advent of genetic testing are likely to propel the Huntington's disease market growth.

However, several factors are impeding the growth of the Huntington's disease market. The lack of approved therapy is a constraint not only for patients but also for pharmaceutical behemoths. Companies are undoubtedly doing their part by developing much-needed therapies; however, the high failure rate of emerging therapies in the Huntington's disease market is the major impediment. So far, several candidates have failed, not just one or two. Both the developer and the Huntington community were optimistic about a few candidates, which turned out to be false. The failure of late-stage candidate tominersen dealt the biggest blow.

Wave Life Sciences recently announced that their two antisense oligonucleotides (ASOs) did not successfully reduce mutant huntingtin levels in Phase I/II studies in Huntington's disease patients, so the company decided to discontinue those products. Tominersen, a Roche/Ionis antisense asset, suffered the same fate. The failure of Roche and Ionis' late-stage candidate, tominersen had already raised questions about Wave's strategy. The development and approval of a novel therapy to treat Huntington's disease is a major unmet need, and only a few companies are currently working toward that goal in the Huntington's disease market.

Report Metrics	Details
Study Period	2019-2032
Coverage	7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Base Year	2019
Huntington's Disease Market CAGR	18.4 %
Huntington's Disease Market Size in 2021	USD 199 Million
Key Huntington's Disease Companies	Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Wave life sciences, Takeda, Medesis Pharm, Ionis Pharmaceuticals, PTC Therapeutics, Novartis, Neurimmune Therapeutics, SOLA Biosciences, Roche, AOP Orphan, Azevan Pharmaceuticals, Asklepios BioPharmaceutical, BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others
Key Pipeline Huntington's DiseaseTherapies	ACR-16 (pridopidine), INGREZZA (valbenazine/NBI-98854), ANX005, SOM3355 (bevantolol), VX15/2503 (pepinemab), SAGE-718, AMT-130 (rAAV5-miHTT), WVE-003 (mHTT SNP3), NP03 (nanolithium)/NanosiRNA, and others

Scope of the Huntington's Disease Market Report

Therapeutic Assessment: Huntington's Disease current marketed and emerging therapies
Huntington's Disease Market Dynamics: Huntington's Disease market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Huntington's Disease Market Access and Reimbursement

Discover more about Huntington's disease drugs in development @ Huntington's Disease Clinical Trials

Table of Contents

1.	Huntington's Disease Market Key Insights
2.	Huntington's Disease Market Report Introduction
3.	Huntington's Disease Market Overview at a Glance
4.	Huntington's Disease Market Executive Summary
5.	Disease Background and Overview
6.	Huntington's DiseaseTreatment and Management
7.	Huntington's DiseaseEpidemiology and Patient Population
8.	Patient Journey
9.	Huntington's Disease Marketed Drugs
10.	Huntington's DiseaseEmerging Drugs
11.	Seven Major Huntington's Disease Market Analysis
12.	Huntington's DiseaseMarket Outlook
13.	Potential of Current and Emerging Therapies
14.	KOL Views
15.	Huntington's Disease Market Drivers
16.	Huntington's Disease Market Barriers
17.	Unmet Needs
18.	SWOT Analysis
19.	Appendix
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

Related Reports

Huntington's Disease Pipeline

Huntington's Disease Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Huntington's disease companies, including Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, among others.

Huntington's Disease Epidemiology Forecast

Huntington's Disease Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted Huntington's disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Wilson Disease Pipeline

Wilson Disease Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Wilson disease companies, including Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, among others.

Wilson Disease Market

Wilson Disease Market Insights, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Wilson disease companies, including Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, among others.

Bipolar Disorder Pipeline

Bipolar Disorder Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar disorder companies, including Vanda Pharmaceuticals, Pear Therapeutics, Sunovion, Lyndra Therapeutics, among others.

Obsessive-Compulsive Disorder Pipeline

Obsessive-Compulsive Disorder Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key obsessive-compulsive disorder companies, including Ceruvia Lifesciences, Biohaven Pharmaceuticals, Octapharma, among others.

Other Trending Reports

Related Healthcare Blogs

Wilson Disease Treatment Outlook

Bipolar Depression Therapeutics Pipeline

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/huntingtons-disease-market-to-witness-upsurge-in-growth-at-a-tremendous-cagr-of-18-4-during-the-study-period-20192032-predicts-delveinsight-301730055.html

Großer Insider-Report 2024 von Dr. Dennis Riedl

Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.

Hier klicken

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche